

Doctor's Order Sheet
**trifluridine/tipiracil 35 -
Mvasi® (bevacizumab)
5 mg/kg Regimen**

Name: _____

HCN: _____

Date of Birth
BirthBirth: _____

ARIA Protocol Name: Trifluridine/Tipiracil 35 Mvasi (bevacizumab) 5
Adult Chemotherapy - Medical Oncology
Unresectable Colorectal Carcinoma

ctal Carcinoma



CC6770 0497 06/2024

Allergies:	<input type="checkbox"/> No Known
Date: <u>DD/MONTH/YYYY</u> Planned Administration Date: <u>DD/MONTH/YYYY</u> Cycle <u> </u> of <u> </u> Cycle Duration: 28 days Date of previous cycle: <u>DD/MONTH/YYYY</u>	
MAY PROCEED WITH DOSES AS WRITTEN IF:	
<ul style="list-style-type: none"> ANC greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $75 \times 10^9/L$, otherwise notify Medical Oncologist LFTs and Bilirubin assessed Creatinine clearance assessed. Assess dipstick urine or laboratory urinalysis for protein 	
PREMEDICATIONS (FOR HOSPITAL PHARMACY):	
<input type="checkbox"/> Other: _____	
CHEMOTHERAPY (FOR HOSPITAL PHARMACY):	
<input type="checkbox"/> Mvasi® (bevacizumab) 5 mg/kg X weight (kg) = _____ mg IV in 100 mL normal saline over 10 minutes on days 1 and 15.	
CHEMOTHERAPY (FOR COMMUNITY PHARMACY):	
<input type="checkbox"/> trifluridine/tipiracil 35 mg/m² X BSA = _____ mg	
<input type="checkbox"/> Dose modification: trifluridine/tipiracil 35 mg/m² X BSA - _____% = _____ mg	
PO BID on days 1 to 5 and days 8 to 12. Round to nearest 5 mg, maximum dose of 80mg.	
This prescription is NOT eligible for pharmacist prescribing by dispensing pharmacist.	

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.